By cross analysis of the DEGs in MS lesions and target genes of matrine injection, 12 key genes were obtained, namely Annexin A1 (ANXA1), Fatty acid binding protein 7 (FABP7), Moesin (MSN), Glycogen phosphorylase L (PYGL), Dipeptidyl peptidase 4 (DPP4), complement C3 (C3), Peroxisome proliferator activated receptor gamma (PPARG), MER proto-oncogene, tyrosine kinase (MERTK), IL-10 receptor subunit alpha (IL10RA), Stratifin (SFN), Angiogenin (ANG), and dishevelled-associated activator of morphogenesis 1 (DAAM1). This evidence concerns the gene ANXA1 and myeloid sarcoma.